IP Library Granted Patent US 8,666,669
Granted Patent B2
US 8,666,669 · App. 10/296,860 · Granted Mar 4, 2014

Method for determining the likelihood that a test polynucleotide sequence differs from a driver polynucleotide

Inventors: Karl Poetter (Northcote, AU); Simon Foote (Fairfield, AU)
Assignee: Genera Biosystems Limited
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,666,669
App. No.
10/296,860
Granted
Mar 4, 2014
Kind
B2
Abstract

The present invention relates generally is a method for determining the likelihood that a test polynucleotide sequence differs from a driver polynucleotide sequence. More particularly, the present method uses fluorescence-based technology in the assessment of the results of competitive hybridization between polynucleotide sequences. The present method does not require nucleotide sequencing or gel electrophoresis and is capable of being multiplexed and automated. The methods of the present invention will find broad application in the analysis of polynucleotides, inter alia in genetic analysis, specific locus testing, genotyping, mutation detection, the discovery and detection of single nucleotide polymorphisms (SNPs) and mapping.

Claims (21)

1. A method of determining a single nucleotide mutation or a single nucleotide difference between a test polynucleotide, from a first nucleic acid sample from a first subject, and a driver polynucleotide sequence, from a second nucleic acid sample from a second subject, the method comprising:

(a) producing the test polynucleotide which corresponds to the driver polynucleotide by amplification from the first nucleic acid sample with a pair of forward and reverse primers including a first label whereby the test polynucleotide is labeled with a first reporter molecule capable of providing a first identifiable signal;

(b) producing complementary driver and target polynucleotides by amplification from the second nucleic acid sample with a pair of forward and reverse primers that amplify the same region in (a) and include a second label whereby the driver polynucleotide is labeled with a second reporter molecule different from the first reporter molecule and capable of providing a second identifiable signal

(c) preparing a composition comprising the labeled test and driver polynucleotides in solution and a target polynucleotide immobilized on a solid support and unlabeled with the first or second reporter molecules wherein the ratio of labeled test to driver polynucleotides present in the composition is from 2:1 to 10:1; and

(d) flow cytometry screening to detect immobilized first and second identifiable signals after subjecting said composition to competitive hybridization conditions comprising a temperature gradient, wherein the driver polynucleotide will more preferentially hybridize to the target polynucleotide than said test polynucleotide when said test polynucleotide differs from said driver polynucleotide by at least one nucleotide;

(e) determining said test polynucleotide differs from said driver polynucleotide by at least one nucleotide when the (D:T)comp is greater than the (D:T)non-comp and said test polynucleotide sequence is not different from said driver polynucleotide sequence when (D:T)comp is not greater than the (D:T)non-comp,

wherein

D is the driver-label;

T is the test-label;

(D:T)comp is the D:T ratio under the competitive hybridization conditions; and

(D:T)non-comp is the D:T ratio under the non-competitive hybridization conditions

wherein the complete nucleotide sequence of either the test polynucleotide and/or the driver polynucleotide is unknown.

2. The method of claim 1 , wherein the single base mutation is centrally-located in said test polynucleotide.

3. The method of claim 1 , wherein the single base mutation is less than 10 bases from either end of the test polynucleotide.

4. The method of claim 1 , wherein the non-competitive hybridization conditions is from 25° C.-42° C.

5. The method of claim 1 , wherein the competitive hybridization conditions is at least 65° C.

6. The method of claim 1 , wherein the temperature gradient comprises a period of about 0.2-10 minutes per degree drop.

7. The method of claim 1 , wherein the temperature gradient is from about Tm+10° C. to about Tm−20 to −25° C.

8. The method of claim 1 , wherein the amounts of the target, driver and test polynucleotides are provided in a ratio of 1:2:10.

9. The method of claim 1 , wherein the amounts of the driver and test polynucleotides are provided in a ratio of 1:5.

10. The method of claim 1 wherein the single base mutation is in one allele.

Assignments (4)
CHANGE OF NAME Recorded Mar 21, 2023
From: BP GENOMICS PTY LIMITED
To: INCITE HEALTH PTY LIMITED
Reel/Frame 063049/0069 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 21, 2023
From: GENERA BIOSYSTEMS LIMITED
To: BP GENOMICS PTY LTD
Reel/Frame 063123/0171 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 31, 2010
From: THE WALTER AND ELIZA HALL INSTITUTE OF MEDICAL RESEARCH
To: GENERA BIOSYSTEMS LIMITED
Reel/Frame 024167/0862 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 19, 2003
From: POETTER, KARL; FOOTE, SIMON
To: WALTER AND ELIZA HALL INSTITUTE OF MEDICAL RESEARCH, THE
Reel/Frame 014080/0085 →
Priority Claims (1)
AU PQ7811 · May 29, 2000 · national
Continuity (1)
Related Publication 20040014065A1 · Jan 22, 2004